CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenues:
Net product sales	$ 3,338,390	$ 2,689,478	$ 1,750,762
Sanofi collaboration revenue	658,665	758,873	541,299
Bayer collaboration revenue	744,270	580,488	495,555
Other revenue	119,102	74,889	31,941
Total revenues	4,860,427	4,103,728	2,819,557
Expenses:
Research and development	2,052,295	1,620,577	1,271,353
Selling, general, and administrative	1,177,697	838,526	519,267
Cost of goods sold	194,624	241,702	129,030
Cost of collaboration and contract manufacturing	105,070	151,007	75,988
Total expenses	3,529,686	2,851,812	1,995,638
Income from operations	1,330,741	1,251,916	823,919
Other income (expense):
Other income (expense), net	6,269	(12,578)	(25,312)
Interest expense	(7,195)	(14,241)	(37,372)
Total other income (expense)	(926)	(26,819)	(62,684)
Income before income taxes	1,329,815	1,225,097	761,235
Income tax expense	(434,293)	(589,041)	(423,109)
Net income	$ 895,522	$ 636,056	$ 338,126
Net income per share - basic	$ 8.55	$ 6.17	$ 3.36
Net income per share - diluted	$ 7.70	$ 5.52	$ 2.98
Weighted average shares outstanding - basic	104,719	103,061	100,612
Weighted average shares outstanding - diluted	116,367	115,230	113,413
Statements of Comprehensive Income
Net income	$ 895,522	$ 636,056	$ 338,126
Other comprehensive income (loss):
Unrealized (loss) gain on marketable securities, net of tax	(21,412)	(43,679)	53,439
Comprehensive income	$ 874,110	$ 592,377	$ 391,565